Chow L H, Mosbach-Ozmen L, Ryffel B, Borel J F
Preclinical Research, Sandoz Ltd., Basel, Switzerland.
Transplantation. 1988 Aug;46(2 Suppl):107S-112S. doi: 10.1097/00007890-198808001-00020.
Cyclosporine-induced graft-versus-host disease has been described in lethally irradiated rats and mice following syngeneic bone marrow reconstitution. To further study this apparently CsA-restricted phenomenon, we followed reported protocols by administering CsA orally at 50 or 100 mg/kg/day to irradiated, syngeneically reconstituted C57B1/6 mice. No clinical evidence of GVHD was observed for more than 8 weeks after CsA discontinuation. Ear biopsies and circulating immunoglobulin levels 2-4 weeks after stopping CsA failed to demonstrate histological or serological evidence of GVHD, respectively, compared with mice allogeneically reconstituted with Balb/c marrow. To further follow a previous report, CsA 50 mg/kg/day orally or 10 mg/kg/day intraperitoneally was given to normal C57B1/6 mice prior to using their spleen or bone marrow cells for reconstitution of lethally irradiated syngeneic mice. Clinical monitoring and histological examination of recipients 2-5 weeks after reconstitution again failed to confirm GVHD. Thus our results were uniformly negative in attempting to reproduce syngeneic GVHD in mice. Existing data on rats and humans are reviewed, showing that syngeneic or autologous GVHD is not CsA-restricted and that the syndrome could be equated to the chronic form of GVHD found in rats and patients after allogeneic bone marrow transplantation.
在同基因骨髓重建后的致死性照射大鼠和小鼠中,已描述了环孢素诱导的移植物抗宿主病。为了进一步研究这种明显受环孢素限制的现象,我们按照已报道的方案,以50或100mg/kg/天的剂量给经照射、同基因重建的C57B1/6小鼠口服环孢素。在停用环孢素后8周以上未观察到移植物抗宿主病的临床证据。与用Balb/c骨髓进行异基因重建的小鼠相比,停用环孢素2-4周后的耳部活检和循环免疫球蛋白水平分别未能显示移植物抗宿主病的组织学或血清学证据。为了进一步遵循先前的报告,在使用正常C57B1/6小鼠的脾脏或骨髓细胞重建致死性照射的同基因小鼠之前,给它们口服50mg/kg/天或腹腔注射10mg/kg/天的环孢素。重建后2-5周对受体进行临床监测和组织学检查,再次未能证实移植物抗宿主病。因此,我们在试图在小鼠中重现同基因移植物抗宿主病方面的结果均为阴性。对大鼠和人类的现有数据进行了综述,结果表明同基因或自体移植物抗宿主病不受环孢素限制,并且该综合征可等同于大鼠和患者在异基因骨髓移植后发现的慢性移植物抗宿主病形式。